Walter A. Munns
Munns presided over the continued growth and diversification of Smith Kline. He orchestrated strategic acquisitions in the consumer and medical business arenas, introduced “Contac” and other Smith Kline medicines to the international market, and expanded investments in research and development. During his tenure he doubled both sales (from $124 million to $259 million) and earnings (from $21 million to $42 million).